Introduction
Hemolytic disease of the fetus and newborn (HDFN) is a clinical condition that occurs as a result of hemolysis of fetal or neonatal red blood cells (RBCs) due to maternal red cell IgG antibodies that can cross the placenta. HDFN is characterized by fetal or neonatal anemia, hyperbilirubinemia and sometimes even fatal hydrops fetalis, and can occur in case of antigenic difference between maternal and fetal RBCs. Clinically significant red cell alloantibodies are those that have the potential to cause hemolysis of red cells bearing the corresponding antigen. 1 Maternal antibodies capable of causing HDFN could either be ABO antibodies or non-ABO alloantibodies that can develop in the mother due to sensitization following a blood transfusion or previous pregnancy with red cell antigenic differences. 2 Before the introduction of RhIG, maternal anti-D alloimmunization was the most common cause of HDFN. However, strict implementation of RhIG prophylaxis has drastically reduced the incidence of anti-D associated HDFN over the last half-century. Introduction of postnatal RhIG administration in the late 1960s brought the incidence of RhD associated HDFN in the USA down from 45.1 per 10,000 births in the early 1970s to 10.6 per 10,000 births in the mid-1980s. 3 Incidence of RhD associated HDFN decreased further to as low as 0.1% with the implementation of antenatal RhIG immunoprophylaxis. 4 Consequently, ABO and other maternal alloantibodies have now emerged as a major cause of HDFN in developed countries. 2 Studies investigating the prevalence of red cell alloantibodies amongst pregnant women have been done in different countries including Croatia, Netherlands, Spain, Nigeria, Norway, Australia, and China. 6, [8] [9] [10] [11] [12] [13] Prevalence of clinically significant red cell alloantibodies has been reported to be anywhere between 0.3% and 3.4% in different studies. [5] [6] [7] [8] [9] [10] [11] [12] [13] Current practice in the USA recommends red cell antibody screening for all pregnant females at their first prenatal visit. However, frequencies and specificities of clinically significant red cell alloantibodies in pregnant females have rarely been reported in the USA; particularly in the Midwestern USA. We conducted a retrospective chart review study to determine the frequency and specificity of clinically significant red cell alloantibodies in pregnant females (based on their ABO and RhD type) who delivered at Beaumont Hospital Royal Oak between May 1, 2017 and December 31, 2017. In addition, we compared our study findings with some similar studies done in the past in different countries of the world.
Methods
Approval for this retrospective chart review study was obtained from the Beaumont Research Institutional Review Board. A waiver of patients' consent was approved by Beaumont Research IRB for this retrospective chart review study as it did not influence the patient care or clinical outcome, nor did this chart review study cause any harm to the patients. Patients' data confidentiality was strictly maintained, and the study was conducted in compliance with the Declaration of Helsinki. Using the Beaumont Health System electronic medical records, 4548 pregnant females were screened based on newborn deliveries that took place at Beaumont Hospital Royal Oak between May 1, 2017 and December 31, 2017. One pregnant female who delivered between these dates was above the age of 50 years and was excluded from the study per IRB approved protocol. We performed a retrospective chart review of the remaining 4547 pregnant females aged between 13 and 50 years who delivered at Beaumont Hospital Royal Oak between these dates. In two out of these 4547 females, ABO group could not be determined, and therefore they were also excluded from the study. The remaining 4545 obstetric patients who had a valid/confirmed ABO RhD typing and a valid red cell antibody screening were included in the study. Types of data that were collected include: patient's age, date of delivery, ABO and RhD type of the pregnant females, red cell antibody screen results, antibody specificity in case of positive red cell antibody screen, history of RhIG administration, gravida status of females with clinically significant alloantibodies, and antibody titers of clinically significant antibodies. Results from duplicate samples from the same patient were excluded from the total. History of RhIG administration during pregnancy was confirmed by review of medical records. Charts of obstetric patients with a positive red cell antibody screen were further reviewed to determine the specificity of red cell alloantibodies. RBC alloantibodies that are known to cause HDFN were considered clinically significant. All anti-D antibodies that developed as a result of documented RhIG administration were considered clinically insignificant in addition to other red cell alloantibodies that are not known to cause HDFN as mentioned in AABB guidelines. 14 ABO/RhD typing and antibody screening were performed using the gel card methodology with automated blood bank analyzers Ortho ProVue, whereas the specificity of antibodies was identified with indirect antiglobulin testing using the manual gel card methodology. Statistical analysis was performed by the biostatistics department at Beaumont Hospital Royal Oak using chi-square for proportion and frequency comparisons to determine the association of ABO and RhD types and the presence of clinically significant alloantibodies.
Results
In this retrospective chart review study, we determined the prevalence and specificity of clinically significant maternal red cell alloantibodies known to cause HDFN according to ABO and RhD type. Out of 4545 females that were included in our study, 440 (9.7%) females had a positive red cell antibody screen, with 34 of them having one or more clinically significant alloantibodies. The remaining 406 pregnant females with a positive red cell antibody screen had only clinically insignificant red cell alloantibodies, including 372 females with RhIG induced anti-D. The prevalence of clinically significant red cell alloantibodies amongst 440 females with positive antibody screen was 7.7% or overall 0.74% amongst all 4545 pregnant females included in our study. Out of 4545 pregnant women included in our study, 44.4% females belonged to blood group O, 35.4% belonged to group A, 15% belonged to group B, and 5.1% females belonged to group AB. Numerical distribution of total pregnant females included in the study as well as females with positive red cell antibody screen according to ABO type is shown in Table 1 . The numbers of pregnant females with clinically significant alloantibodies by blood group O, A, B, and AB were 10, 16, 5 and 3, respectively, making a total of 34. The likelihood (prevalence rate) that group O females with positive red cell antibody screen had a clinically significant alloantibody was 5.5%, as compared to 9.2% for group A, 8.6% for group B and 11.1% for group AB females. In pregnant females with positive red cell antibody screen, prevalence ratio (for clinically significant red cell alloimmunization) with respect to blood group O was calculated to be 1.68 for group A, 1.57 for group B and 2.02 for group AB females. No significant association (p-value >0.05) was found between ABO groups and the presence of clinically significant alloantibodies in females with positive red cell antibody screen ( Table 1) .
Out of 4545 pregnant females included in our study, 3998 (88%) females were RhD positive and 547 (12%) females were RhD negative. Out of the 34 obstetric patients with clinically significant alloantibodies, 28 (82.4%) were RhD positive and 6 (17.6%) were RhD negative. In regards to RhD type, prevalence rate and prevalence ratio for having clinically significant red cell alloantibodies in females with positive red cell antibody screen are shown in Table 2 . There was a significant association between RhD type and the presence of clinically significant alloantibodies (chi-square p-value <0.001) amongst females with positive antibody screen. Females with positive red cell antibody screen (n=440) 69 371
Prevalence rate of positive red cell antibody screen 1.7% 67.8% Females with clinically significant alloantibodies (n=34) 28 6
Prevalence rate of clinically significant alloantibodies in females with positive red cell antibody screen 40.6% 1.6%
Prevalence ratio of clinically significant alloantibodies in females with positive red cell antibody screen 1.00 0.04 p-values (in females with positive red cell antibody screen)
<0.001
In our study, 28 out of 34 females with clinically significant red cell antibodies were multigravida and 6 females were primigravida ( Table 3) . Out of 34 females with clinically significant red cell alloantibodies, 6 (17.6%) females had more than one clinically significant alloantibody; all of them being multigravida, indicating a higher risk of multiple red cell alloimmunization with subsequent pregnancies. Twenty-five out of 34 (73.5%) females were identified to have the clinically significant alloantibody during their second or subsequent pregnancy; whereas 9 (26.5%) females had clinically significant red cell alloantibody during their first pregnancy (2 out of these 9 females were identified to have the alloantibody even prior to their first pregnancy).
Overall, in our study population, the most frequently identified clinically significant red cell alloantibody was anti-E (n=13; 38.2%) followed by anti-K (n=7; 20.6%) and anti-M (n=6; 17.6%). The total number of clinically significant alloantibodies identified in 34 females was 42 with 14 different antibody specificities. Distribution of identified clinically significant alloantibodies according to ABO and RhD type is shown in Table 4 . Out of all 34 females with clinically significant alloantibodies, only one female with anti-K had a critical titer of 1:16 at some point during her pregnancy, but no adverse clinical outcome was reported in the mother or neonate. Three out of 34 females with clinically significant alloantibodies required blood transfusion during pregnancy (1 due to sickle cell disease, 1 due to beta-thalassemia minor and 1 due to alpha thalassemia trait).
Discussion
HDFN is an important clinical entity that needs to be dealt with aggressively to avoid undesirable clinical outcomes. HDFN due to anti-D alloimmunization was a major cause of fetal and neonatal mortality until the early 1970s. 3 Introduction and implementation of RhIG administration over the last few decades have significantly reduced the 
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Journal of Blood Medicine 2019:10 incidence of anti-D associated HDFN to as low as 0.1%, particularly in developed countries, 4 and red cell alloantibodies other than anti-D have now emerged as a major cause of HDFN. 2 Prevalence of clinically significant red cell alloimmunization in pregnant females reported in studies from different countries ranges between 0.3% and 3.4%. [5] [6] [7] [8] [9] [10] [11] [12] [13] In our study, the prevalence of clinically significant red cell alloimmunization was 740 per 100,000 pregnant females (0.74%).
In our study, a total of 440 females (9.7%) out of 4545 screened females had positive red cell antibody screen. Results from Smith et al 7 showed a presence of RBC antibodies in 3% of all the screened obstetric patients and a presence of clinically significant alloantibodies in 40.5% of these patients or in 1.2% of all obstetric patients included in the study. The difference in the prevalence of positive antibody screen between our study and the study by Overall clinically significant red cell alloimmunization prevalence in our study was 0.74% or 740 per 100,000 pregnant females. This is somewhat higher than that reported by Dajak et al 6 (0.42%) in Croatia and Solves et al 9 (0.63%) in Spain, but lower than the prevalence reported by Smith et al 7 (1.2%) and Jeremiah et al 10 (3.4%). Koelewijn et al 15 reported the prevalence of pregnancies with clinically significant alloantibodies other than anti-D to be 0.3% (328 in 100,000). In a 12-month study conducted in the Malay population, 30 (0.58%) out of 5163 pregnant females were found to have clinically significant red cell alloantibodies. 5 In a longitudinal cohort study conducted by De Vrijer et al 8 in the Netherlands, 2392 pregnant females were screened and the overall incidence of red cell alloimmunization was reported to be 2.7%, with the incidence of non-RhD alloantibodies to be 1.6%. Lee et al 13 conducted a retrospective study in Hong Kong from 1997 to 2001 that included 26,883 pregnant females and reported the prevalence of significant red cell alloantibodies to be 0.31% in the overall study population and 0.27% amongst females with Chinese ethnicity.
The most frequently identified significant alloantibody in our study was anti-E (38.2%) followed by anti-K (20.6%) and anti-M (17.6%). In a study conducted by Hassan et al 5 in the Malay population, anti-E (33.3%) followed by anti-D (10%) were the two most commonly identified significant alloantibodies. In the study conducted by Smith et al, 7 the three most frequently identified clinically significant antibodies were anti-E (31%) followed by anti-M (24.3%) and anti-D (18.7%). Jeremiah et al 10 in their study from Nigeria reported the prevalence of clinically significant red cell alloantibodies to be 3.4% in pregnant females, with anti-C being the most frequent followed by anti-K. In a cohort study 11 involving 55,462 consecutive antibody screening tests from a tertiary Western Norwegian Hospital, the two most frequent RBC alloantibodies in pregnant women were anti-M (20.8%) and anti-D (18.9%). The most prevalent clinically significant red cell alloantibody identified by Pal and Williams 12 was also anti-E (27.6%), followed by anti-D (10.4%), anti-K (9.5%) and anti-C (8.7%). In the study conducted by Koelewijn et al, 15 the most common non-RhD alloantibody was also anti-E followed by anti-K and anti-C.
The second most frequently identified significant red cell alloantibody in our study population was anti-K. Out of 34 pregnant females with clinically significant red cell alloantibodies, 7 (20.6%) were found to have anti-K with an overall prevalence of 0.15%, which is higher than in some other studies. 6, 15 Fetal anemia in case of anti-K alloimmunization is mainly caused by the suppression of marrow erythropoiesis directly induced by anti-K antibodies, as opposed to other alloantibodies which act mainly by causing direct hemolysis. 17, 18 Anti-K was the second most frequently identified significant alloantibody after anti-D in the study conducted by Dajak et al 6 and accounted for almost 13% of all clinically significant red cell alloantibodies with an overall prevalence of 0.05%. Koelewijn et al 15 reported the prevalence of anti-K antibodies to be 79 per 100,000, or 0.08%.
In our study, anti-M was identified in 6 out of 34 patients having clinically significant alloantibodies and was identified as the most frequent alloantibody in group B obstetric patients. Anti-M is mostly an IgM naturally occurring antibody, but the IgG class of anti-M has also been reported to cause HDFN. 19, 20 Frequency of anti-M has been reported to be 10% in pregnant women with positive antibody screen. 21 Wikman et al 21 reported anti-M in a female during her three consecutive pregnancies causing severe HDFN, with one fetus dying at 20 weeks of gestation due to hydrops fetalis.
In our study population, anti-E (n=13; 46.4%) followed by anti-M (n=6; 21.4%) were the most frequently identified clinically significant alloantibodies in RhD positive females, whereas anti-K (n=4; 66.6%), followed by anti-D (n=2; 33.3%) and anti-C (n=2; 33.3%) were the most frequently identified antibodies in RhD negative pregnant females. Results from a study by Smith et al 7 showed anti-E followed by anti-M and anti-K to be the most frequently identified significant alloantibodies amongst RhD positive females, whereas anti-D followed by anti-C and anti-E were the most frequently identified alloantibodies in RhD negative females.
In our study, out of 34 females with clinically significant red cell alloantibodies, 6 (17.6%) females had more than one clinically significant alloantibody. This is comparable to the findings of Solves et al 9 who identified multiple clinically significant alloantibodies in 17.0% of pregnant females with clinically significant red cell alloantibodies.
Lastly, in regards to RhD status, our study results showed significant association between RhD type and the presence of clinically significant red cell alloantibodies amongst females with positive antibody screen, implicating that amongst RhD positive females with a positive red cell antibody screen, the likelihood (prevalence rate) of having a clinically significant alloantibody was 40.6%, whereas it was 1.6% for RhD negative females with a positive red cell antibody screen. In contrast, the overall prevalence rate of positive red cell antibody screen was much higher in RhD negative females as compared to RhD positive females (67.8% and 1.7%, respectively), which was mostly due to prophylactically administered RhIG induced clinically insignificant anti-D causing positive antibody screen in RhD negative females.
Conclusion
The overall prevalence of clinically significant red cell alloantibodies in our study population was 0.74%, which is slightly higher than the prevalence reported in European countries, and somewhat lower than in South Asian and African countries. This difference is likely due to genetic and racial variations in different parts of the world, different study population sizes, and possibly some difference in blood bank testing methodologies. Anti-E and anti-K were the two most frequently identified clinically significant red cell alloantibodies in our study population. The findings of our study aim to re-emphasize the importance of screening and detection of red cell alloantibodies early in pregnancy to help identify and appropriately manage high-risk pregnancies, in addition to increasing the understanding amongst pregnant females about these antibodies and the associated risk of HDFN. We recommend minimizing the exposure of females of childbearing age to incompatible red blood cell antigens through unnecessary transfusions to help further reduce the overall incidence of red cell alloimmunization as well as the risk of HDFN.
